Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

Author:

Yu Jinghua1,Zhang Hua23,Zhang Yifan1,Zhan Yan1,Ma Sheng23,Hu Tao1,Zhang Ning1,Lou Yangtong4,Bao Hanying4,Xu Zusheng4,Zhong Dafang1,Miao Liyan23,Diao Xingxing1

Affiliation:

1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

2. Department of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China

3. Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China

4. Shanghai Yingli Pharmaceutical Co., Ltd, Shanghai, China

Funder

Shanghai Yingli Pharmaceutical Co., Ltd.

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Reference27 articles.

1. Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy

2. Targeting PI3K/AKT/mTOR network for treatment of leukemia

3. Mass Balance Studies, with a Focus on Anticancer Drugs

4. Umbralisib: First Approval

5. FDA US 2020. Safety testing of drug metabolites guidance for industry. [accessed 2020 30 April 2020]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3